β2-ar agonists Search Results


β 2 -ar agonists  (Novartis)
90
Novartis β 2 -ar agonists
β 2 Ar Agonists, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β 2 -ar agonists/product/Novartis
Average 90 stars, based on 1 article reviews
β 2 -ar agonists - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
selective β 2 -ar agonist clenbuterol hydrochloride  (Hikma Inc)
90
Hikma Inc selective β 2 -ar agonist clenbuterol hydrochloride
A Rate of glucose disposal (Rd) during the high-insulin phase corrected for baseline (µmol/kg/min) ( p = 0.032). B Rate of glucose disposal during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min). C Baseline endogenous glucose production (EGP) (µmol/kg/min). D Endogenous glucose production suppression during the low-insulin phase of the hyperinsulinemic-euglycemic clamp (%). E Non-oxidative glucose disposal (NOGD) during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min) (low-insulin: p = 0.032). F Non-oxidative glucose disposal during the high-insulin phase corrected for baseline (µmol/kg/min). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, <t>clenbuterol:</t> n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.
Selective β 2 Ar Agonist Clenbuterol Hydrochloride, supplied by Hikma Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/selective β 2 -ar agonist clenbuterol hydrochloride/product/Hikma Inc
Average 90 stars, based on 1 article reviews
selective β 2 -ar agonist clenbuterol hydrochloride - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
β2-ar agonist salbutamol  (Dawley Inc)
90
Dawley Inc β2-ar agonist salbutamol
A Rate of glucose disposal (Rd) during the high-insulin phase corrected for baseline (µmol/kg/min) ( p = 0.032). B Rate of glucose disposal during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min). C Baseline endogenous glucose production (EGP) (µmol/kg/min). D Endogenous glucose production suppression during the low-insulin phase of the hyperinsulinemic-euglycemic clamp (%). E Non-oxidative glucose disposal (NOGD) during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min) (low-insulin: p = 0.032). F Non-oxidative glucose disposal during the high-insulin phase corrected for baseline (µmol/kg/min). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, <t>clenbuterol:</t> n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.
β2 Ar Agonist Salbutamol, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β2-ar agonist salbutamol/product/Dawley Inc
Average 90 stars, based on 1 article reviews
β2-ar agonist salbutamol - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
β2-ar agonist terbutaline  (AstraZeneca ltd)
90
AstraZeneca ltd β2-ar agonist terbutaline
A Rate of glucose disposal (Rd) during the high-insulin phase corrected for baseline (µmol/kg/min) ( p = 0.032). B Rate of glucose disposal during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min). C Baseline endogenous glucose production (EGP) (µmol/kg/min). D Endogenous glucose production suppression during the low-insulin phase of the hyperinsulinemic-euglycemic clamp (%). E Non-oxidative glucose disposal (NOGD) during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min) (low-insulin: p = 0.032). F Non-oxidative glucose disposal during the high-insulin phase corrected for baseline (µmol/kg/min). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, <t>clenbuterol:</t> n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.
β2 Ar Agonist Terbutaline, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β2-ar agonist terbutaline/product/AstraZeneca ltd
Average 90 stars, based on 1 article reviews
β2-ar agonist terbutaline - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
β2-ar agonists  (Cowen Inc)
90
Cowen Inc β2-ar agonists
A Rate of glucose disposal (Rd) during the high-insulin phase corrected for baseline (µmol/kg/min) ( p = 0.032). B Rate of glucose disposal during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min). C Baseline endogenous glucose production (EGP) (µmol/kg/min). D Endogenous glucose production suppression during the low-insulin phase of the hyperinsulinemic-euglycemic clamp (%). E Non-oxidative glucose disposal (NOGD) during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min) (low-insulin: p = 0.032). F Non-oxidative glucose disposal during the high-insulin phase corrected for baseline (µmol/kg/min). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, <t>clenbuterol:</t> n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.
β2 Ar Agonists, supplied by Cowen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β2-ar agonists/product/Cowen Inc
Average 90 stars, based on 1 article reviews
β2-ar agonists - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
selective β2ar agonist hexaprenaline sulfate  (Nycomed)
90
Nycomed selective β2ar agonist hexaprenaline sulfate
A Rate of glucose disposal (Rd) during the high-insulin phase corrected for baseline (µmol/kg/min) ( p = 0.032). B Rate of glucose disposal during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min). C Baseline endogenous glucose production (EGP) (µmol/kg/min). D Endogenous glucose production suppression during the low-insulin phase of the hyperinsulinemic-euglycemic clamp (%). E Non-oxidative glucose disposal (NOGD) during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min) (low-insulin: p = 0.032). F Non-oxidative glucose disposal during the high-insulin phase corrected for baseline (µmol/kg/min). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, <t>clenbuterol:</t> n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.
Selective β2ar Agonist Hexaprenaline Sulfate, supplied by Nycomed, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/selective β2ar agonist hexaprenaline sulfate/product/Nycomed
Average 90 stars, based on 1 article reviews
selective β2ar agonist hexaprenaline sulfate - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
β2-ar agonist terbutaline  (Dawley Inc)
90
Dawley Inc β2-ar agonist terbutaline
A Rate of glucose disposal (Rd) during the high-insulin phase corrected for baseline (µmol/kg/min) ( p = 0.032). B Rate of glucose disposal during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min). C Baseline endogenous glucose production (EGP) (µmol/kg/min). D Endogenous glucose production suppression during the low-insulin phase of the hyperinsulinemic-euglycemic clamp (%). E Non-oxidative glucose disposal (NOGD) during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min) (low-insulin: p = 0.032). F Non-oxidative glucose disposal during the high-insulin phase corrected for baseline (µmol/kg/min). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, <t>clenbuterol:</t> n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.
β2 Ar Agonist Terbutaline, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β2-ar agonist terbutaline/product/Dawley Inc
Average 90 stars, based on 1 article reviews
β2-ar agonist terbutaline - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
β2-ar-agonist  (National Research Council Canada)
90
National Research Council Canada β2-ar-agonist
A Rate of glucose disposal (Rd) during the high-insulin phase corrected for baseline (µmol/kg/min) ( p = 0.032). B Rate of glucose disposal during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min). C Baseline endogenous glucose production (EGP) (µmol/kg/min). D Endogenous glucose production suppression during the low-insulin phase of the hyperinsulinemic-euglycemic clamp (%). E Non-oxidative glucose disposal (NOGD) during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min) (low-insulin: p = 0.032). F Non-oxidative glucose disposal during the high-insulin phase corrected for baseline (µmol/kg/min). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, <t>clenbuterol:</t> n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.
β2 Ar Agonist, supplied by National Research Council Canada, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β2-ar-agonist/product/National Research Council Canada
Average 90 stars, based on 1 article reviews
β2-ar-agonist - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


A Rate of glucose disposal (Rd) during the high-insulin phase corrected for baseline (µmol/kg/min) ( p = 0.032). B Rate of glucose disposal during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min). C Baseline endogenous glucose production (EGP) (µmol/kg/min). D Endogenous glucose production suppression during the low-insulin phase of the hyperinsulinemic-euglycemic clamp (%). E Non-oxidative glucose disposal (NOGD) during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min) (low-insulin: p = 0.032). F Non-oxidative glucose disposal during the high-insulin phase corrected for baseline (µmol/kg/min). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, clenbuterol: n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial

doi: 10.1038/s41467-023-35798-5

Figure Lengend Snippet: A Rate of glucose disposal (Rd) during the high-insulin phase corrected for baseline (µmol/kg/min) ( p = 0.032). B Rate of glucose disposal during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min). C Baseline endogenous glucose production (EGP) (µmol/kg/min). D Endogenous glucose production suppression during the low-insulin phase of the hyperinsulinemic-euglycemic clamp (%). E Non-oxidative glucose disposal (NOGD) during the hyperinsulinemic-euglycemic clamp at baseline, low- and high-insulin phases (µmol/kg/min) (low-insulin: p = 0.032). F Non-oxidative glucose disposal during the high-insulin phase corrected for baseline (µmol/kg/min). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, clenbuterol: n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Article Snippet: In a randomised, placebo-controlled, double-blinded, cross-over design participants received either the selective β 2 -AR agonist clenbuterol hydrochloride (2 × 20 μg/day) (Spiropent, Hikma Pharmaceuticals, Portugal) or a placebo for two weeks with a four week wash-out period (Fig. ).

Techniques:

A GLUT4 content at the myocellular cell membrane (arb. units). B Total GLUT4 content (arb. units). C GLUT4 content in the myocellular cytosol (arb. units) D Representative images of GLUT4 immunohistochemistry staining for three participants, scale bar 50 µm. E Phosphorylation of mTORS2481 as a marker of mTORC2 activation (arb. units). Both samples of a participant were run on the same blot for comparison. All data were analyzed by means of a two-sided Wilcoxon signed-rank test. A – D n = 9 per group, E n = 10 per group. P = placebo, Cl = clenbuterol. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial

doi: 10.1038/s41467-023-35798-5

Figure Lengend Snippet: A GLUT4 content at the myocellular cell membrane (arb. units). B Total GLUT4 content (arb. units). C GLUT4 content in the myocellular cytosol (arb. units) D Representative images of GLUT4 immunohistochemistry staining for three participants, scale bar 50 µm. E Phosphorylation of mTORS2481 as a marker of mTORC2 activation (arb. units). Both samples of a participant were run on the same blot for comparison. All data were analyzed by means of a two-sided Wilcoxon signed-rank test. A – D n = 9 per group, E n = 10 per group. P = placebo, Cl = clenbuterol. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Article Snippet: In a randomised, placebo-controlled, double-blinded, cross-over design participants received either the selective β 2 -AR agonist clenbuterol hydrochloride (2 × 20 μg/day) (Spiropent, Hikma Pharmaceuticals, Portugal) or a placebo for two weeks with a four week wash-out period (Fig. ).

Techniques: Membrane, Immunohistochemistry, Staining, Phospho-proteomics, Marker, Activation Assay, Comparison

A Systolic pressure (mmHg). B Diastolic pressure (mmHg). C Heart rate (beats/min) ( p = 0.003). D Baseline femoral artery blood flow velocity (arb. units) ( p = 0.014). E Baseline femoral artery diameters (mm) ( p = 0.005). F Flow-mediated vasodilation (%). G Flow-mediated vasodilation corrected for peak velocity flow stimulus (%). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, Clenbuterol: n = 11. * p < 0.05, ** p < 0.01. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial

doi: 10.1038/s41467-023-35798-5

Figure Lengend Snippet: A Systolic pressure (mmHg). B Diastolic pressure (mmHg). C Heart rate (beats/min) ( p = 0.003). D Baseline femoral artery blood flow velocity (arb. units) ( p = 0.014). E Baseline femoral artery diameters (mm) ( p = 0.005). F Flow-mediated vasodilation (%). G Flow-mediated vasodilation corrected for peak velocity flow stimulus (%). All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Placebo: n = 11, Clenbuterol: n = 11. * p < 0.05, ** p < 0.01. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Article Snippet: In a randomised, placebo-controlled, double-blinded, cross-over design participants received either the selective β 2 -AR agonist clenbuterol hydrochloride (2 × 20 μg/day) (Spiropent, Hikma Pharmaceuticals, Portugal) or a placebo for two weeks with a four week wash-out period (Fig. ).

Techniques:

A Sleeping metabolic rate (SMR) (kJ/min) ( p = 0.002). B Respiratory exchange ratio. C Carbohydrate oxidation during the night (g/min). D Fat oxidation during the night (g/min). SMR sleeping metabolic rate, RER respiratory exchange ratio, CHO carbohydrate. All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Clenbuterol: n = 11, Placebo: n = 11. ** p < 0.01. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial

doi: 10.1038/s41467-023-35798-5

Figure Lengend Snippet: A Sleeping metabolic rate (SMR) (kJ/min) ( p = 0.002). B Respiratory exchange ratio. C Carbohydrate oxidation during the night (g/min). D Fat oxidation during the night (g/min). SMR sleeping metabolic rate, RER respiratory exchange ratio, CHO carbohydrate. All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Clenbuterol: n = 11, Placebo: n = 11. ** p < 0.01. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Article Snippet: In a randomised, placebo-controlled, double-blinded, cross-over design participants received either the selective β 2 -AR agonist clenbuterol hydrochloride (2 × 20 μg/day) (Spiropent, Hikma Pharmaceuticals, Portugal) or a placebo for two weeks with a four week wash-out period (Fig. ).

Techniques:

A Plasma glucose concentrations (mmol/L). B Plasma insulin concentrations (mU/L). C Plasma triglyceride concentrations (mmol/L) ( p = 0.02). D Plasma free fatty acid concentrations (µmol/L). FFA free fatty acid. All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Clenbuterol: n = 11, Placebo: n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial

doi: 10.1038/s41467-023-35798-5

Figure Lengend Snippet: A Plasma glucose concentrations (mmol/L). B Plasma insulin concentrations (mU/L). C Plasma triglyceride concentrations (mmol/L) ( p = 0.02). D Plasma free fatty acid concentrations (µmol/L). FFA free fatty acid. All data were analyzed by means of a two-sided Wilcoxon signed-rank test. Clenbuterol: n = 11, Placebo: n = 11. * p < 0.05. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Article Snippet: In a randomised, placebo-controlled, double-blinded, cross-over design participants received either the selective β 2 -AR agonist clenbuterol hydrochloride (2 × 20 μg/day) (Spiropent, Hikma Pharmaceuticals, Portugal) or a placebo for two weeks with a four week wash-out period (Fig. ).

Techniques: Clinical Proteomics

A Systolic blood pressure (mmHg). B Diastolic blood pressure (mmHg). C Heart rate (beats/min). All data were analyzed by means of a linear mixed model analysis without correction for multiple comparisons. Clenbuterol: n = 11. Placebo: n = 11. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial

doi: 10.1038/s41467-023-35798-5

Figure Lengend Snippet: A Systolic blood pressure (mmHg). B Diastolic blood pressure (mmHg). C Heart rate (beats/min). All data were analyzed by means of a linear mixed model analysis without correction for multiple comparisons. Clenbuterol: n = 11. Placebo: n = 11. Data are presented as mean ± SEM. Source data are provided as a Source Data file.

Article Snippet: In a randomised, placebo-controlled, double-blinded, cross-over design participants received either the selective β 2 -AR agonist clenbuterol hydrochloride (2 × 20 μg/day) (Spiropent, Hikma Pharmaceuticals, Portugal) or a placebo for two weeks with a four week wash-out period (Fig. ).

Techniques: